Intech Investment Management LLC has $20.30M stock position in Pfizer Inc. (NYSE:PFE)

Intech Investment Management LLC raised its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 30.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 725,663 shares of the biopharmaceutical company’s stock after buying an additional 168,724 shares during the period. Intech Investment Management LLC’s holdings in Pfizer were worth $20,304,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. FAS Wealth Partners Inc. boosted its holdings in shares of Pfizer by 1.3% during the second quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company’s stock worth $736,000 after buying an additional 342 shares during the period. Sachetta LLC boosted its holdings in shares of Pfizer by 7.3% in the second quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 342 shares during the period. Ironvine Capital Partners LLC boosted its holdings in shares of Pfizer by 2.1% in the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock worth $470,000 after buying an additional 353 shares during the period. Secure Asset Management LLC raised its stake in shares of Pfizer by 0.6% in the second quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company’s stock worth $1,632,000 after purchasing an additional 353 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. raised its stake in Pfizer by 0.8% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical company’s stock worth $1,180,000 after purchasing an additional 355 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s shares.

Pfizer stock fell 0.3%

Shares of Pfizer stock opened at $29.67 on Friday. Pfizer Inc. it has a fifty-two week low of $25.20 and a fifty-two week high of $34.11. The stock has a market cap of $168.13 billion, a PE ratio of -494.42, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. The company’s 50-day simple moving average is $29.35 and its 200-day simple moving average is $28.20. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60, and a current ratio of 0.86.

Pfizer (NYSE:PFE – Get Free Report ) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. In the same period last year, the company earned $0.67 per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer announces dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a $0.42 dividend. This represents a dividend of $1.68 on an annualized basis and a yield of 5.66%. The ex-dividend date of this dividend was Friday, July 26. Pfizer’s payout ratio is -2,799.53%.

Analysts on Wall Street are forecasting an increase

A number of equities analysts recently weighed in on PFE shares. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Barclays boosted their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54, according to MarketBeat.

Get the latest research report on Pfizer

Pfizer profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United States, Europe and internationally. The company offers drugs and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine and women’s health under the brands Eliquis, Nurtec ODT/Vydura, Zavzpret and Premarin; infectious diseases with unmet medical needs under the family brands Prevnar, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; and the prevention and treatment of COVID-19 and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured stories

Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.